Evidence map›Paper›PMID 42774809›Full record

ReviewFrontiers in physiology2026

Mitochondrial retrograde signaling in gastric cancer: mtDNA mutations, ROS-driven NF-κB/HIF-1α activation, and Warburg effect amplification.

Yanyan Bai, Wenbin Chen

Abstract readReview
In one paragraph

Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yanyan BaiShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Wenbin ChenShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial retrograde signaling serves as a critical communication axis that links mitochondrial dysfunction to nuclear gene expression, shaping key pathways in gastric carcinogenesis. Gastric tumors frequently exhibit somatic mtDNA mutations, impaired oxidative phosphorylation, and elevated reactive oxygen species (ROS), collectively driving transcriptional reprogramming through activation of NF-κB and stabilization of HIF-1α. These retrograde signals promote inflammation, metabolic reprogramming, and resistance to apoptosis, ultimately reinforcing the Warburg phenotype characterized by enhanced aerobic glycolysis and lactate production. This review synthesizes current evidence on how mtDNA mutations, ROS-dependent transcription factor activation, and mitochondrial-nuclear metabolic crosstalk converge to promote malignant transformation. By integrating insights from mitochondrial biology, cancer genetics, and metabolic regulation, we outline a mechanistic framework that highlights mitochondrial retrograde signaling as a promising therapeutic target in gastric cancer.

Indexed as

gastric cancermetabolic reprogrammingmitochondrial retrograde signalingmtDNA mutationsreactive oxygen species

Identifiers

PMID42774809
PMCPMC13595338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.